Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant.

Julie M. Vose, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Izidore S. Lossos, MD, Annette Ervin-Haynes, DO, Kenichi Takeshita, MD, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2570.

https://doi.org/10.1182/blood.V110.11.2570.2570

Published: 2007

Journal Articles

Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Thomas E. Witzig, MD, Julie M. Vose, MD, Timothy D. Moore, MD, Craig B. Reeder, MD, Craig E. Cole, MD, Glen Justice, MD, Henry P. Kaplan, MD, Michael Voralia, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Peter H. Wiernik, MD

Blood (2007) 110 (11): 2560.

https://doi.org/10.1182/blood.V110.11.2560.2560

Published: 2007

Journal Articles

Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma.

Joseph M. Tuscano, MD, Izidore S. Lossos, MD, Glen Justice, MD, Julie M. Vose, MD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2563.

https://doi.org/10.1182/blood.V110.11.2563.2563

Published: 2007

Journal Articles

Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Izidore S. Lossos, MD, Peter H. Wiernik, MD, Glen Justice, MD, Joseph M. Tuscano, MD, Craig E. Cole, MD, Julie M. Vose, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2564.

https://doi.org/10.1182/blood.V110.11.2564.2564

Published: 2007

Journal Articles

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Peter H. Wiernik, MD, Izidore S. Lossos, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Craig E. Cole, MD, Kyle McBride, MS, Kenton Wride, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2565.

https://doi.org/10.1182/blood.V110.11.2565.2565

Published: 2007

Journal Articles

Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

Peter H. Wiernik, MD, Izidore Lossos, MD, Joseph Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD,PhD, Thomas M. Habermann, MD

Blood (2006) 108 (11): 531.

https://doi.org/10.1182/blood.V108.11.531.531

Published: 2006

Journal Articles

Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Thomas E. Witzig, MD, Julie M. Vose, MD, Henry P. Kaplan, MD, Jeffrey Lee Wolf, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Peter H. Wiernik, MD

Blood (2006) 108 (11): 2482.

https://doi.org/10.1182/blood.V108.11.2482.2482

Published: 2006

Journal Articles

Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Laurie DiMiceli, Swaminathan Padmanabhan, MD, David Lawrence, Zale P. Bernstein, MD, Kenichi Takeshita, MD, David Spaner, Paul Wallace, MD, Catriona Byrne, Cynthia Crystal, Myron S. Czuczman, MD

Blood (2005) 106 (11): 447.

https://doi.org/10.1182/blood.V106.11.447.447

Published: 2005

Journal Articles

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Asher Alban Chanan-Khan, MD, Kena Miller, NP, Alexandra Koryzna, RN, Kenichi Takeshita, MD, Philip McCarthy, MD, Alice Mohr, NP, Kathleen Donohue, Zale P. Bernstein, MD, Arif Alam, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 3476.

https://doi.org/10.1182/blood.V104.11.3476.3476

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant.

Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma.

Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only